Clinical and health care resource use burden of hospitalizations for oral factor Xa inhibitor‐associated major bleeding: A real‐world analysis of Medicare beneficiaries
Abstract Objective To characterize the burden of illness associated with oral factor Xa (FXa) inhibitor‐related bleeding in the US Medicare population. Methods This retrospective cohort study used the full 20% Medicare random sample claims database to identify patients who experienced their first ho...
Main Authors: | James M. Williams, Belinda Lovelace, Mary J. Christoph, Suying Li, Haifeng Guo, Madison Hoover, Craig I. Coleman |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-06-01
|
Series: | Journal of the American College of Emergency Physicians Open |
Subjects: | |
Online Access: | https://doi.org/10.1002/emp2.12956 |
Similar Items
-
Definition of factor Xa inhibitor–related, life‐threatening gastrointestinal bleeding and guidance on when to use reversal therapy: A Delphi panel
by: Gregory J. Fermann, et al.
Published: (2023-10-01) -
Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis
by: Xiehui Chen, et al.
Published: (2021-10-01) -
Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most
by: Mauricio Concha, et al.
Published: (2024-01-01) -
Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants
by: Anne Gulbech Ording, et al.
Published: (2021-07-01) -
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
by: Olivia S. Costa, et al.
Published: (2022-06-01)